TY - JOUR
T1 - Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia
T2 - what is the evidence regarding adverse effects?
AU - De la Torre Canales, Giancarlo
AU - Poluha, Rodrigo Lorenzi
AU - Lora, Victor Muñoz
AU - Araújo Oliveira Ferreira, Dyna Mara
AU - Stuginski-Barbosa, Juliana
AU - Bonjardim, Leonardo Rigoldi
AU - Cury, Altair Antoninha Del Bel
AU - Conti, Paulo César Rodrigues
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objectives: The objective of the study was to conduct a systematic review of literature assessing botulinum toxin type A (BoNT-A) safety and adverse effects in the treatment of myofascial pain (MFP) and trigeminal neuralgia (TN). Materials and methods: The search for articles by two specific researchers involved the PubMed, EMBASE, Web of Science, and Scopus databases. Specific terms were used, and no publication time and language restrictions were applied. Clinical trials that investigated the effects of BoNT-A among participants with myofascial pain in masticatory muscles or trigeminal neuralgia were considered eligible for this systematic review. Data for each study were extracted and analyzed according to a PICO-like structured reading. Results: The search strategy provided 436 citations. After analysis, 16 citations were included, seven for MFP and nine for TN. In all studies, BoNT-A was well tolerated and improved pain. The most common adverse effects were temporary regional weakness, tenderness over the injection sites, and minor discomfort during chewing. Most studies reported a spontaneous resolution of adverse effect. Conclusions: It can be concluded that BoNT-A treatment is well tolerated, since minor adverse effects were the most frequently reported; however, it is recommended that future studies aim to assess the safety and possible adverse effects of multiples applications or high doses of this treatment. Clinical relevance: BoNT-A has been increasingly diffused in dentistry, being used for the management of masticatory myofascial pain and trigeminal neuralgia. Nonetheless, there is no consensus about its efficacy and adverse effects that could occur when this treatment is applied.
AB - Objectives: The objective of the study was to conduct a systematic review of literature assessing botulinum toxin type A (BoNT-A) safety and adverse effects in the treatment of myofascial pain (MFP) and trigeminal neuralgia (TN). Materials and methods: The search for articles by two specific researchers involved the PubMed, EMBASE, Web of Science, and Scopus databases. Specific terms were used, and no publication time and language restrictions were applied. Clinical trials that investigated the effects of BoNT-A among participants with myofascial pain in masticatory muscles or trigeminal neuralgia were considered eligible for this systematic review. Data for each study were extracted and analyzed according to a PICO-like structured reading. Results: The search strategy provided 436 citations. After analysis, 16 citations were included, seven for MFP and nine for TN. In all studies, BoNT-A was well tolerated and improved pain. The most common adverse effects were temporary regional weakness, tenderness over the injection sites, and minor discomfort during chewing. Most studies reported a spontaneous resolution of adverse effect. Conclusions: It can be concluded that BoNT-A treatment is well tolerated, since minor adverse effects were the most frequently reported; however, it is recommended that future studies aim to assess the safety and possible adverse effects of multiples applications or high doses of this treatment. Clinical relevance: BoNT-A has been increasingly diffused in dentistry, being used for the management of masticatory myofascial pain and trigeminal neuralgia. Nonetheless, there is no consensus about its efficacy and adverse effects that could occur when this treatment is applied.
KW - Adverse effects
KW - Bone loss
KW - Botulinum toxins
KW - Muscle atrophy
KW - Muscle paralysis
KW - Muscle weakness
UR - http://www.scopus.com/inward/record.url?scp=85069739548&partnerID=8YFLogxK
U2 - 10.1007/s00784-019-03026-4
DO - 10.1007/s00784-019-03026-4
M3 - Review article
C2 - 31342244
AN - SCOPUS:85069739548
SN - 1432-6981
VL - 23
SP - 3411
EP - 3421
JO - Clinical Oral Investigations
JF - Clinical Oral Investigations
IS - 9
ER -